Timber Pharmaceuticals

Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded in 2019 and is headquartered in Basking Ridge, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2023

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trex Wind-down, Inc. engages in the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibroma in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded on August 30, 2010 and is headquartered in Warren, NJ.

Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany

Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis

Virtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET

Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward Outlook

BASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire  -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Company has received formal notice from The NYSE American LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American's continued listing standards.

Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001-

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results

BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –  Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced today that it will effect a 1-for-50 reverse stock split of its outstanding common stock. Subject to NYSE American (“NYSE” or the “Exchange”) approval, the Company anticipates that trading will resume on the NYSE American on an as-adjusted basis as of the commencement of trading on Wednesday, November 9, 2022. As previously announced, the trading of the Company's shares of common stock was halted by the Exchange due to the low trading price of the Company's shares of common stock on November 1, 2022. Although not anticipated by the Company, the Exchange could maintain the trading halt. The Exchange could also suspend trading and move to delist the Company's common stock if the price per share post-split does not meet the requirements of Section 1003(f)(v) of the NYSE American Company Guide.

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split

Timber Pharmaceuticals Announces Halt of Common Stock Trading

- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application - - Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the Treatment of X-Linked Recessive Ichthyosis -

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has entered into a securities purchase agreement with several institutional accredited investors to sell in a registered direct offering (i) 13,000,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), and (ii) Series 1 common warrants (the “Series 1 Warrants”) to purchase up to an aggregate of 13,000,000 shares of Common Stock at a purchase price of $0.10 per share and associated warrant. The Series 1 Warrants will be immediately exercisable at an exercise price of $0.10 per share and will expire two and one-half years following the initial exercise date.

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

European Commission expected to issue its decision on orphan designation in approximately 30 days

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

BASKING RIDGE, NJ, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it had received a deficiency letter ("Letter") from NYSE American LLC ("NYSE American" or the "Exchange") stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

- Company announces positive clinical data of FDA-Designated Breakthrough Therapy TMB-001 demonstrating safety, efficacy and quality of life improvements in congenital ichthyosis patients will be presented in seven abstracts -

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

- Previously reported study demonstrated clinically meaningful efficacy with a favorable safety profile for TMB-001 in moderate to severe congenital ichthyosis -

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Clarus Therapeutics Holdings

Palisade Bio

T2 Biosystems

Penny stocks under $1 to watch this week. The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week

Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results

Endo International

Here's what you need to know about trading penny stocks on August 10th The post Best Penny Stocks to Buy Now? 3 For Your August List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Now? 3 For Your August List

Basking Ridge, NJ, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the closing of its previously announced public offering of 66,666,667 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 66,666,667 shares of its common stock at an offering price to the public of $0.12 per share (or pre-funded warrant) and associated warrant. The warrants have an exercise price of $0.12 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

Basking Ridge, NJ, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the pricing of a public offering of 66,666,667 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 66,666,667 shares of its common stock at an offering price to the public of $0.12 per share (or pre-funded warrant) and associated warrant. The warrants will have an exercise price of $0.12 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.  The closing of the offering is expected to occur on or about August 8, 2022, subject to the satisfaction of customary closing conditions.

Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada, Italy, France, and Germany

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial -

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

Imperial Petroleum

IT Tech Packaging Inc

Are these under $1 penny stocks on your watchlist? The post Best Penny Stocks to Buy Under $1?

Best Penny Stocks to Buy Under $1? 3 to Watch as April Ends

Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days

Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis

Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results

Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype

Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting

Basking Ridge, New Jersey--(Newsfile Corp. - February 28, 2022) - Timber Pharmaceuticals (NYSE American: TMBR) today announced that John Koconis, Chairman and CEO will be attending the Q1 Virtual Investor Summit. John Koconis, Chairman and CEO, will present a corporate overview, including the positive Phase 2b study results for TMB-001, its lead asset, and its plans to initiate a Phase 3 trial in Q2 2022. Event:Q1 Investor SummitDate:

News for Timber Pharmaceuticals Stock (TMBR)